Introduction
============

The calcineurin inhibitor (CNI), such as tacrolimus (TAC) and mTOR inhibitor (mTORi), such as everolimus (EVR) are immunosuppressive drugs helpful to prevent allograft rejection and simultaneously improve graft and patient survival in kidney transplantation ([@B16]).

TAC and EVR binding to their cytoplasmic protein receptor, the FK506-binding protein 12 (FKBP12). The TAC-FKBP12 complex interacts with calcineurin while the EVR-FKBP12 targets mTOR. These complexes lead to inhibition of T cell activation and proliferation, besides other important implications in alloimmune responses ([@B34]; [@B3]).

The therapeutic monitoring of these immunosuppressants is widely accepted because there is high between-patient variability in their pharmacokinetics and concentration--effect relationship ([@B35]). In this way, in addition to biodemographic and clinical factors, genetics play an important role. The key genetic variants involved in the metabolism and distribution of the immunosuppressive drugs have been largely investigated ([@B25]; [@B45]). On the contrary, those involved with drug targets and molecular signaling pathway remain poorly known in solid organ transplantation.

In kidney transplant recipients on CNI-based immunosuppression, some polymorphisms in three calcineurin subunit genes (*PPP3CA*, *PPP3CB*, and *PPP3R1*) were not associated with renal function and incidence of rejection or adverse events ([@B22]; [@B26]; [@B29]).

Five variants in *MTOR* (rs1770345, rs2300095, rs2076655, rs1883965, and rs12732063) were investigated in kidney transplant recipients switched from CNI to mTORi. The AGAAA haplotype was associated with a slightly decreasing in hemoglobin levels ([@B36]), but it seems that it was due to the physiological mechanism rather than pharmacogenetic ([@B27]).

This study investigated the influence of polymorphisms in *MTOR*, *PPP3CA*, *FKBP1A* (FKBP12), *FKBP2*, and *FOXP3* on long-term clinical outcomes (renal function, acute rejection and adverse events) of kidney recipients treated with TAC and EVR-based immunosuppressive therapy. *FKBP2* encodes the FKBP13 that is closely related to FKBP12 ([@B34]). FOXP3 is a key transcriptional factor of the regulatory T cells (Tregs), which are important in suppressing alloimmune responses and maintenance of transplantation tolerance ([@B6]).

Materials and Methods {#s1}
=====================

Study Population
----------------

This pharmacogenetic study was carried out in a sample of kidney transplant recipients previously enrolled in the clinical trial registered as NCT01354301 at the US Clinical Trials database ([@B33]). The study was approved by the Ethics Committee of the UNIFESP (Protocol \# 0339/11) and performed according to the international regulations in Good Clinical Practices and to the ethical principles of the Declaration of Helsinki. All patients provided written informed consent prior to enrollment.

The aforementioned trial included low/moderate-immunological risk adult recipients indicated for first ABO-compatible kidney transplantation, from either alive or deceased donor, of which, the 269 patients who completed the study were selected. Exclusion criteria considered kidneys from HLA identical or expanded criteria deceased donors, positive cytotoxic cross match or panel reactive antibody equal to or above 50%, either class I or class II. Use of contraceptives methods during the trial were requested for women of childbearing potential ([@B33]).

Immunosuppressive Regimens
--------------------------

The patients were randomized in three study groups of immunossupressive treatment, as follows: (i) Group TAC5/EVR: single dose of anti-thymocyte globulin at first day post-transplant, TAC 0.05 mg/kg b.i.d. and EVR 1.5 mg daily b.i.d.; (ii) TAC10/EVR: basiliximab induction on days 0 and 4. On day 1, TAC 0.1 mg/kg b.i.d. and EVR 1.5 mg b.i.d.; (iii) TAC10/MPS: basiliximab induction on days 0 and 4. On day 1, TAC 0.1 mg/kg b.i.d. and MPS 720-mg b.i.d. Before transplantation, all patients were treated with 1 g of methylprednisolone, and began receiving on day 1 post-transplant 0.5 mg/kg/day oral prednisone (not exceeding a 30 mg dose) tapered to 5 mg/day dose by day 45.

Clinical Characteristics and Laboratory Data
--------------------------------------------

Clinical characteristics and laboratory data of the kidney recipients were recorded pre- and post-transplant). Clinical characteristics included cause of CKD, dialysis procedure, maintenance hemodialysis, cold ischemia time, graft loss and DGF. Laboratory data consisted of serum creatinine, eGFR, glucose, insulin, total cholesterol, HDL and LDL cholesterol, triglycerides, hemoglobin, erythrocytes and leukocyte counts, urinary proteins, immunodiagnostic test for CMV, kidney graft biopsies. eGFR was estimated by MDRD formula ([@B15]).

Immunosuppressive Drug Monitoring
---------------------------------

TAC and EVR blood concentration, the prescribed doses and adjusted concentration for dose administered (Co/D) were recorded. Blood concentrations were analyzed by chemoluminiscent microparticle immunoassay (Abbott Diagnostics, Lake Forest, IL, United States) and liquid chromatography-tandem mass spectrometry, respectively.

Clinical Outcomes
-----------------

Primary clinical outcomes were considered serum creatinine, eGFR, cellular and humoral acute kidney rejection, and CMV events, including asymptomatic (infection) or symptomatic (disease) viremia ([@B13]).

Secondary clinical outcomes were considered the adverse events that were classified according to the Medical Dictionary for Regulatory activities ([@B20]), as: blood and lymphatic system disorders, gastrointestinal disorders, general disorders and administration site conditions, metabolism and nutrition disorders, and renal and urinary disorders. Recurrence of adverse event was not considered in the analysis of the secondary outcomes.

Genomic DNA Extraction
----------------------

Genomic DNA was isolated from peripheral blood sample using the QIAamp^®^ DNA Blood Mini Kit (Qiagen Inc., Valencia, CA, United States) on the QIAcube system (Qiagen Sciences Inc., Germantown, MD, United States). DNA quantification and purity were evaluated by 260/280 nm spectrophotometry using NanoDrop ND-1000 (NanoDrop Technologies Inc., Wilmington, NC, United States) and DNA integrity was evaluated by 1.0% agarose gel electrophoresis. Samples were stored at −20°C.

Gene Polymorphisms Selection and Analysis
-----------------------------------------

Gene polymorphisms \[*MTOR* rs1057079 (c.4731G\>A, p.Ala1577=), rs1135172 (c.1437T\>C, p.Asp479=) and rs1064261 (c.2997C\>T, p.Asn999=); *PPP3CA* rs3730251 (c.249G\>A, p.Ala83=); *FKBP1A* rs6033557 (n. 259+24936T\>C); *FKBP2* rs2159370 (c.-2110G\>T); and *FOXP3* rs2232365 (c.-22-902A\>G), and rs3761548 (c.-23+2882A\>C)\] were selected using a two-step approach based on pathway-gene method, as described elsewhere ([@B12]).

Genotyping was performed using the following pre-designed TaqMan SNP genotyping assays (Thermo Fisher Scientific Inc., Foster City, CA, United States): C_8862305_1 (rs1057079), C_8862346_10 (rs1135172), C_28027381_10 (rs1064261), C_25618069_10 (rs3730251), C\_\_30149598_20 (rs6033557), C\_\_\_2981262_20 (rs2159370), C\_\_15942641_10 (rs2232365), C\_\_27476877_10 (rs3761548). The PCR mixture contained 1X TaqMan genotyping master mix, 1X TaqMan SNP genotyping assay and 40 ng of template DNA. The real-time PCR assays were carried out according to the manufacturer's instructions using an ABI 7500 FAST system (Applied Biosystems, Foster City, CA, United States). Genotype calling was performed using 7500 SDS software (Thermo Fisher Scientific Inc., Foster City, CA, United States). To assess the accuracy of the genotype calling, 20% of the DNA samples were randomly genotyped twice.

Statistical Analysis
--------------------

Continuous variables are expressed as median and interquartile range and compared by Mann--Whitney or Kruskal--Wallis test and Bonferroni's correction test for multiple comparisons. Categorical variables are expressed as percentage and number of individuals in parenthesis, and compared by chi-square test or likelihood ratio test (for number of individuals less than 5).

Allele and genotype frequencies were estimated by counting. Hardy--Weinberg equilibrium (HWE) was estimated using Haploview program ([@B2]). For polymorphisms located at X chromosome HWE was estimated considering only female individuals in order to avoid hemizygous male genotypes.

The influence of gene polymorphisms on clinical outcomes was studied using dominant, co-dominant and recessive inheritance models. The dominant model, in which the presence of at least one minor allele has an effect on the phenotype or clinical outcome, provides the highest power values of the statistical tests ([@B10]). Therefore, homozygous and heterozygous patients carrying the minor allele were analyzed together.

Cumulative incidence of acute rejection episodes (time-dependent variable) during the follow-up was analyzed by Kaplan--Meier survival analysis, and comparisons between major and minor allele carriers were performed using the log-rank test.

Univariable logistic regression analysis was used to assess the relationship between gene variants and primary and secondary clinical outcomes. Continuous variables such as eGFR and serum creatinine were divided by tertiles to be used as categorical variables in the logistic regression analysis. The combined effect of covariates and SNP was investigated using multivariable logistic regression analysis. The covariates considered in the models were age, weight, gender, donor type, time on hemodialysis, DGF time, cold ischemia time, acute rejection, proteinuria, immunosuppressive therapy group and CMV. Only covariates with *p*-value lower than 0.15 in univariable logistic regression analysis were included in the multivariable logistic regression ([@B9]). To account for multiple hypothesis testing in model with more than two covariates, adjustment of *p*-values was performed using Bonferroni--Holm sequential correction method.

Association analysis of *MTOR* polymorphisms with primary and secondary outcomes was carried out with data from groups treated with EVR (TAC5/EVR and TAC10/EVR), which is the mTORi in the immunosuppressive therapy.

The statistical analyses were performed using the SPSS for windows (SPSS Inc., Chicago, IL, United States), GraphPad Prism (GraphPad Software Inc., La Jolla, CA, United States) and SigmaStat (Systat Software Inc., San Jose, CA, United States). The *p*-value threshold for significance was 0.05.

Results
=======

Characteristics of the Study Population
---------------------------------------

Biodemographic and clinical characteristics of the kidney transplant recipients are shown in Table [1](#T1){ref-type="table"}. Median age and weight of the kidney recipients were 44.0 \[34.0--56.0\] years and 68.3 \[59.0--77.9\] kg, respectively. The studied group had mainly men (66.2%) and Caucasians (51.7%). Other self-reported ethnicities were African (14.9%) and intermediate/mixed (33.4%). Causes of CKD were glomerulonephritis (12.3%), hypertension (10.0%) and diabetes (10.0%). Hemodialysis was the most frequent dialysis procedure (93.3%) lasting a median time of 33.0 \[16.0--54.0\] months. Grafts were exposed to cold ischemia for 20.3 \[17.6--23.0\] h. DGF was observed in 33.8% of the kidney recipients, and it lasted 10.0 \[6.0--15.0\] days. Kidney grafts were mainly obtained from deceased donors (69.1%). The proportion of these variables did not differ among the therapy groups, except for graft loss which was higher in the TAC10/MPS group (7.5%) compared to TAC5/EVR (1.3%) and TAC10/EVR (1.0%) (*p* = 0.026).

###### 

Biodemographic and pre-transplant clinical data of kidney recipients.

  Variables                      Total (269)           TAC5/EVR (80)         TAC10/EVR (96)        TAC10/MPS (93)        *p*-Value
  ------------------------------ --------------------- --------------------- --------------------- --------------------- -----------
  Recipient age, years           44.0 \[34.0--56.0\]   43.5 \[32.3--55.8\]   46.0 \[33.5--57.0\]   43.0 \[35.0--55.5\]   0.667
  Recipient weight, kg           68.3 \[59.0--77.9\]   68.8 \[62.4--77.5\]   67.5 \[58.1--76.9\]   68.5 \[57.3--79.8\]   0.652
  Recipient gender, male         66.2% (178)           63.8% (51)            65.6% (63)            68.8% (64)            
  Recipient ethnics, Caucasian   51.7% (139)           47.5% (38)            51.0% (49)            55.9% (52)            0.386
  Cause of CKD                                                                                                           0.260
  Glomerulonephritis             12.3% (33)            13.8% (11)            14.6% (14)            8.6% (8)              
  Hypertension                   10.0% (27)            10.0% (8)             7.3% (7)              12.9% (12)            
  Diabetes                       10.0% (27)            8.8% (7)              5.2% (5)              16.1% (15)            
  Undetermined                   41.6% (112)           41.3% (33)            46.9% (45)            36.6% (34)            
  Other                          26.0% (70)            26.3% (21)            26.0% (25)            25.8% (24)            
  Hemodialysis                   93.3% (251)           91.3% (73)            95.8% (92)            92.5% (86)            0.586^∗^
  Time on hemodialysis, months   33.0 \[16.0--54.0\]   36.0 \[16.0--48.0\]   27.5 \[16.3--49.8\]   29.5 \[16.0--61.5\]   0.894
  Cold ischemia time^a^, h       20.3 \[17.6--23.0\]   20.3 \[17.6--23.7\]   20.5 \[17.8--23.0\]   20.1 \[17.2--23.0\]   0.839
  Delayed graft function         33.8% (91)            37.5% (30)            34.4% (33)            30.1% (28)            0.586
  DGF time, days                 10.0 \[6.0--15.0\]    12.0 \[6.8--16.0\]    11.0 \[6.0--14.0\]    9.0 \[5.3--13.5\]     0.396
  Graft loss                     3.3% (9)              1.3% (1)              1.0% (1)              7.5% (7)              0.026^∗^
  Donor type, deceased           69.1% (186)           77.5% (62)            64.6% (62)            66.7% (62)            0.148

Categorical variables are shown as percentage and number of individuals in parenthesis and compared by chi-square or likelihood ratio (

∗

) tests. Continuous variables are shown as median \[interquartile range\] and compared by Kruskal--Wallis test followed by Bonferroni test for multiple comparisons.

a

Cold ischemia time was estimated for grafts received from deceased donors. CKD, chronic kidney disease; DGF, delayed graft function.

Drug monitoring data of the kidney recipients at 1-year post-transplant is shown in Supplementary Table [1](#SM1){ref-type="supplementary-material"}. TAC concentration was higher in TAC10/MPS group compared to TAC5/EVR and TAC10/EVR groups (\<0.05), while TAC Co/Do were similar among the therapy groups. EVR monitoring data did not differ between the TAC5/EVR and TAC10/EVR groups (*p* \> 0.05).

Clinical Outcomes
-----------------

Primary and secondary kidney outcomes at 1-year post-transplant are shown in Table [2](#T2){ref-type="table"}. In the total group, serum creatinine and eGFR were 1.3 \[1.1--1.6\] mg/dL and 63.5 \[49.7--78.2\] ml/min/1.73 m^2^, respectively. TAC10/EVR group had higher serum creatinine and lower eGFR compared to TAC10/MPS group (*p* \< 0.05). Acute rejection occurred in 14.9% of the patients, mainly T cell-mediated episodes (13.4%), but it did not differ among the treatment groups (*p* = 0.198).

###### 

Primary and secondary clinical outcomes of kidney recipients at 1-year post-transplant.

  Variables                                                  Total (269)           TAC5/EVR (80)              TAC10/EVR (96)           TAC10/MPS (93)           *p*-Value
  ---------------------------------------------------------- --------------------- -------------------------- ------------------------ ------------------------ ------------
  **Primary outcomes**                                                                                                                                          
  Serum creatinine, mg/dL                                    1.3 \[1.1--1.6\]      1.3 \[1.1--1.7\]^a,b^      1.4 \[1.1--1.8\]^a^      1.2 \[1.0--1.5\]^b^      0.034
  eGFR, ml/min/1.73 m^2^                                     63.5 \[49.7--78.2\]   64.6 \[48.9--79.1\]^a,b^   57.8 \[44.6--70.7\]^a^   67.3 \[55.7--81.5\]^b^   0.014
  Acute rejection,                                           14.9% (40)            10.0% (8)                  17.7% (17)               16.2% (15)               0.198
  Cellular                                                   13.4% (36)            7.5% (6)                   17.7% (17)               14.0% (13)               
  Humoral                                                    1.5% (4)              2.5% (2)                   0.0% (0)                 2.2% (2)                 
  **Secondary outcomes**                                                                                                                                        
  *Blood and lymphatic system disorders*                                                                                                                        
  Anemia                                                     8.2% (22)             10.0% (8)                  9.4% (9)                 5.4% (5)                 0.470
  Leukopenia                                                 5.2% (14)             5.0% (4)                   1.0% (1)                 9.7% (9)                 0.018^∗^
  **Gastrointestinal disorders**                                                                                                                                
  Constipation                                               12.6% (34)            11.3% (9)                  10.4% (10)               16.1% (15)               0.450
  Diarrhea                                                   25.7% (69)            25.0% (20)                 22.9% (22)               29.0% (27)               0.621
  Dyspeptic disorder                                         8.6% (23)             3.8% (3)                   9.4% (9)                 11.8% (11)               0.156
  Epigastric pain                                            12.3% (33)            11.3% (9)                  9.4% (9)                 16.1% (15)               0.348
  Nausea and/or vomiting                                     9.7% (26)             8.8% (7)                   10.4% (10)               9.7% (9)                 0.933
  **General disorders and administration site conditions**                                                                                                      
  Edema                                                      41.3% (111)           45.0% (36)                 47.9% (46)               31.2% (29)               0.047
  **Infections and infestations**                                                                                                                               
  Cytomegalovirus                                            18.2% (49)            5.0% (4)                   10.4% (10)               37.6% (35)               \<0.001^∗^
  **Metabolism and nutritional disorders**                                                                                                                      
  Hyperglycemia                                              17.8% (48)            25.0% (20)                 15.6% (15)               14.0% (13)               0.131
  Post-transplant diabetes                                   10.4% (28)            13.8% (11)                 11.5% (11)               6.5% (6)                 0.268
  **Renal and urinary disorders**                                                                                                                               
  Proteinuria                                                8.9% (24)             10.0% (8)                  9.4% (9)                 7.5% (7)                 0.835

Categorical variables are shown as percentage and number of individuals in parenthesis and compared by chi-square or likelihood ratio (

∗

) tests. Continuous variables are shown as median \[interquartile range\] and compared by Kruskal--Wallis test and Bonferroni test for multiple comparisons. Different superscript letters indicate significant differences. eGFR, estimated glomerular filtration rate.

Analysis of the secondary outcomes showed that the most common blood and lymphatic system disorders were anemia (8.2%) and leucopenia (5.2%). Leukopenia was more frequent in the TAC10/MPS group (9.7%) than the TAC5/EVR (5.0%) and TAC10/EVR (1.0%) groups (*p* = 0.018) (Table [2](#T2){ref-type="table"}). Gastrointestinal disorders were mainly constipation (12.6%), diarrhea (25.7%), dyspeptic disorder (8.6%), epigastric pain (12.3%) and nausea and/or vomiting (9.7%), but frequencies of these events were similar among the therapy groups (*p*. \> 0.05). Edema was the most common general disorder (41.3%) with the higher proportion in TAC5/EVR (45.0%) and TAC10/EVR (47.9%) groups than in the TAC10/MPS (31.2%) (*p* = 0.047). CMV infection and/or disease was detected in 18.2% of the total group, but it was more frequent in TAC10/MPS group (37.6%) compared with the other groups (*p* \< 0.001). Hyperglycemia (17.8%) and post-transplant diabetes (10.4%) were the common metabolism and nutritional disorders. Proteinuria, a renal and urinary disorder, was detected in 8.9% of the total kidney recipients.

Gene Polymorphisms and Primary Clinical Outcomes
------------------------------------------------

Frequencies of gene polymorphisms in the sample population are summarized in Table [3](#T3){ref-type="table"}. Genotypes and minor allele frequencies of the SNP were similar among the study groups (*p* \> 0.05). Further, no deviation from HWE was observed (data not shown). These results are suggestive that patients were randomly distributed in the therapy groups.

###### 

Frequencies of gene polymorphisms in kidney transplant recipients.

  Polymorphism         Genotypes   Total (269)   TAC5/EVR (80)   TAC10/EVR (96)   TAC10/MPS (93)   *p*-Value
  -------------------- ----------- ------------- --------------- ---------------- ---------------- -----------
  *MTOR* rs1135172     CC          33.5% (90)    32.5% (26)      39.6% (38)       28.0% (26)       0.534
  c.1437T\>C           CT          47.2% (127)   46.3% (37)      43.8% (42)       51.6% (48)       
                       TT          19.3% (52)    21.3% (17)      16.7% (16)       20.4% (19)       
                       T allele    42.9%         44.4%           38.5%            46.2%            0.290
  *MTOR* rs1064261     TT          42.4% (114)   35.0% (28)      46.9% (45)       44.1% (41)       0.530
  *c.*2997C\>T         TC          45.7% (123)   50.0% (40)      43.8% (42)       44.1% (41)       
                       CC          11.9% (32)    15.0% (12)      9.4% (9)         11.8% (11)       
                       C allele    34.8%         40.0%           31.3%            33.9%            0.218
  *MTOR* rs1057079     AA          33.1% (89)    30.0% (24)      40.6% (39)       28.0% (26)       0.138
  c.4731G\>A           AG          43.9% (118)   40.0% (32)      39.6% (38)       51.6% (48)       
                       GG          23.0% (62)    30.0% (24)      19.8% (19)       20.4% (19)       
                       G allele    45.0%         50.0%           39.6%            46.2%            0.135
  *PPP3CA* rs3730251   GG          85.5% (230)   86.3% (69)      87.5% (84)       82.8% (77)       0.481^∗^
  c.249G\>A            GA          14.1% (38)    12.5% (10)      12.5% (12)       17.2% (16)       
                       AA          0.4% (1)      1.3% (1)        0.0% (0)         0.0% (0)         
                       A allele    7.4%          7.5%            6.3%             8.6%             0.684^∗^
  *FKBP1A* rs6033557   TT          43.9% (118)   37.5% (30)      46.9% (45)       46.2% (43)       0.209
  n.259+24936T\>C      TC          44.6% (120)   48.8% (39)      46.9% (45)       38.7% (36)       
                       CC          11.5% (31)    13.8% (11)      6.3% (6)         15.1% (14)       
                       C allele    33.8%         38.1%           29.7%            34.4%            0.244
  *FKBP2* rs2159370    GG          33.5% (90)    32.5% (26)      34.4% (33)       33.3% (31)       0.997
  c.-2110G\>T          GT          52.0% (140)   53.8% (43)      51.0% (49)       51.6% (48)       
                       TT          14.5% (39)    13.8% (11)      14.6% (14)       15.1% (14)       
                       T allele    40.5%         40.6%           40.1%            40.9%            0.988
  *FOXP3* rs2232365    GG          52.8% (142)   51.3% (41)      55.2% (53)       51.6% (48)       0.721
  c.-22-902A\>G        GA          18.2% (49)    16.3% (13)      20.8% (20)       17.2% (16)       
                       AA          29.0% (78)    32.5% (26)      24.0% (23)       31.2% (29)       
                       A allele    38.1%         40.6%           34.4%            39.8%            0.426
  *FOXP3* rs3761548    CC          65.1% (175)   67.5% (54)      63.5% (61)       64.5% (60)       0.666
  c.-23+2882A\>C       CA          13.0% (35)    15.0% (12)      10.4% (10)       14.0% (13)       
                       AA          21.9% (59)    17.5% (14)      26.0% (25)       21.5% (20)       
                       A allele    28.4%         25.0%           26.0%            28.5%            0.433

Genotype and minor allele frequencies are shown as percentage and number of individuals in parenthesis, and compared by chi-square or likelihood ratio (

∗

) tests.

Median values of serum creatinine at 1-year post-transplant were higher in subjects carrying *MTOR* c.1437T\>C CC genotype and *FOXP3* c.-23+2882A\>C CC genotype (Figure [1](#F1){ref-type="fig"}). The association of gene polymorphisms with the pre-transplant levels of serum creatinine was further investigated, and no differences were found between carriers of the different genotypes of *MTOR* (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). However, individuals carrying the *FOXP3* c.-23+2882CC genotype had higher values of pre-transplant serum creatinine than A allele (genotype CA+AA) carriers (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). The studied polymorphisms did not influence eGFR values (data not shown). We also investigated the influence of *MTOR* c.1437T\>C and *FOXP3* c.-23+2882A\>C variants on TAC blood concentrations at month 12 but no significant differences were found between genotype carriers (*p* \> 0.05) (data not shown). This result is suggestive that immunosuppressant concentration did not influence in the association between genetic variants and serum creatinine.

![Influence of *MTOR* and *FOXP3* variants on serum creatinine in kidney recipients at 1-year post-transplant. Data are shown as median and interquartile range, and were compared by Mann--Whitney test. Comparisons between *MTOR* c.1437T\>C genotypes were carried with data from TAC5/EVR and TAC10/EVR groups.](fphar-09-01296-g001){#F1}

Univariable logistic regression showed that *FOXP3* c.-23+2882CC genotype was associated with increased serum creatinine at 1-year post-transplant (OR = 1.75, 95% CI = 1.07--2.86, *p* = 0.025) (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Patient weight and gender and acute rejection were also variables associated with increased risk for high serum creatinine (*p* \< 0.05), independently of the groups therapy tested (models 1 and 2) (Supplementary Table [3](#SM1){ref-type="supplementary-material"}).

Multivariable regression analysis revealed that male gender remained a risk factor for high serum creatinine at 1-year post-transplant using both model 1 (TAC5/EVR and TAC10/EVR) and model 2 (all therapy groups) (adjusted *p* \< 0.05), while acute rejection was confirmed only using the model 2 (adjusted *p* = 0.024) (Table [4](#T4){ref-type="table"}).

###### 

Variables associated with primary outcomes in kidney recipients at 1-year post-transplant: Multivariable logistic regression analysis.

  Dependent variables            Independent variables         Risk factor      OR (95% CI)          *p*-Value   Adjusted *p*-value
  ------------------------------ ----------------------------- ---------------- -------------------- ----------- --------------------
  **High serum creatinine**                                                                                      
  Model 1                        *MTOR* c.1437T\>C             CC genotype      1.66 (0.86--3.32)    0.104       0.312
                                 Weight                        Per 1 kg         1.01 (0.99--1.04)    0.325       0.442
                                 Gender                        Male             2.97 (1.46--7.49)    0.001       0.005
                                 Acute rejection               Presence         3.51 (1.35--13.04)   0.015       0.060
                                 Proteinuria                   Presence         1.72 (0.69--4.85)    0.221       0.442
  Model 2                        *FOXP3* c.-23+2882A\>C        CC genotype      1.22 (0.69--2.22)    0.465       0.516
                                 Age                           Per 1 year       0.99 (0.97--1.00)    0.112       0.448
                                 Weight                        Per 1 kg         1.02 (0.99--1.04)    0.172       0.516
                                 Gender                        Male             3.67 (1.96--7.80)    0.0001      0.001
                                 Acute rejection               Presence         3.74 (1.71--10.40)   0.004       0.024
                                 Proteinuria                   Presence         1.71 (0.73--4.55)    0.226       0.516
                                 Therapy group                 TAC+EVR          1.82 (1.05--3.31)    0.019       0.095
  **Acute rejection episodes**                                                                                   
  Model 1                        *MTOR* c.4731G\>A             AG+GG genotype   3.53 (1.09--11.48)   0.037       0.111
                                 Age                           Per 1 year       0.97 (0.94--1.01)    0.130       0.260
                                 Weight                        Per 1 kg         1.03 (0.99--1.06)    0.144       0.260
                                 Delayed graft function time   Per 1 day        1.09 (1.03--1.15)    0.003       0.012
  Model 2                        Age                           Per 1 year       0.98 (0.95--1.00)    0.072       0.072
                                 Delayed graft function time   Per 1 day        1.11 (1.06--1.16)    0.0001      0.0001

Model 1: Analysis for MTOR polymorphisms was carried out with data from TAC5/EVR and TAC10/EVR groups. Model 2: Analysis for all polymorphisms except MTOR was performed with data from the TAC5/EVR, TAC10/EVR and TAC10/MPS groups. Adjusted p-value was estimated using the Bonferroni--Holm sequential correction method. OR, odds ratio; CI, confidence interval.

Association of genetic and non-genetic variables associated with acute rejection within 1-year post-transplant was also tested by univariate regression analysis (Supplementary Table [4](#SM1){ref-type="supplementary-material"}). *MTOR* c.4731G allele (AG+GG genotype) carriers had increased risk for acute rejection (OR = 3.37, 95% CI = 1.10--10.30, *p* = 0.037). Moreover, patients with increased DGF time have higher risk of acute rejection using both model 1 (*p* = 0.001) and model 2 (*p* = 0.0001).

Multivariable regression analysis showed that *MTOR* c.4731G allele remained associated with acute rejection (*p* = 0.037), but not after Bonferroni--Holm correction (adjusted *p* = 0.111), whereas increased DGF time was confirmed as a risk factor for rejection (adjusted *p* \< 0.05) (Table [4](#T4){ref-type="table"}).

The influence of *MTOR* c.4731G\>A on 1-year cumulative incidence of acute rejection was further investigated using the Kaplan--Meier survival analysis. Patients carrying the G allele (AG+GG genotype) had higher cumulative incidence of acute rejection (18.6%) compared to AA genotype carriers (6.3%; log-rank *p* \< 0.027) (Figure [2](#F2){ref-type="fig"}).

![One-year cumulative incidence of acute rejection in kidney recipients stratified by *MTOR* c.4731G\>A genotypes. Log-rank *p*-value was estimated by Kaplan--Meier survival analysis.](fphar-09-01296-g002){#F2}

Gene Polymorphisms and Secondary Clinical Outcomes
--------------------------------------------------

The results of the univariable regression analysis for gene polymorphism and other variables associated with secondary clinical outcomes within 1-year post-transplant of kidney recipients are shown in Supplementary Table [5](#SM1){ref-type="supplementary-material"}. *FKBP2* c.-2110GG genotype (OR = 3.87, 95% CI = 1.26--11.91, *p* = 0.018), therapy group (TAC+MPS; OR = 3.66, 95% CI = 1.19--11.28, *p* = 0.024) and CMV (OR = 9.68, 95% CI = 3.08--30.38, *p* = 0.0001) were associated with leukopenia (*p* \< 0.05). *FKBP1A* n.259+24936C allele (TC+CC genotype) was associated with constipation (OR = 2.40, 95% CI = 1.08--5.37, *p* = 0.033). *FOXP3* c.-22-902A allele (GA+AA genotype) was associated with epigastric pain (OR = 2.15, 95% CI = 1.01--4.56, *p* = 0.047) and *FOXP3* c.-23+2882A allele (CA+AA genotype) was associated with nausea and/or vomiting episodes (OR = 2.38, 95% CI = 1.05--5.38, *p* = 0.038).

Multivariable regression analysis showed that *FKBP2* c.-2110GG genotype did not remained associated with leukopenia using the model 1 (adjusted *p* = 0.085) (Table [5](#T5){ref-type="table"}). The *FKBP1A* and *FOXP3* variants were associated, respectively, with constipation and epigastric pain using the model 2 (*p* \< 0.05), but these results were not confirmed after Bonferroni--Holm correction (adjusted *p* \> 0.05).

###### 

Variables associated with secondary outcomes in kidney recipients at 1-year post-transplant: Multivariable logistic regression analysis.

  Dependent variable       Independent variable       Risk factor          OR (95% CI)          *p*-Value   Adjusted *p*-value
  ------------------------ -------------------------- -------------------- -------------------- ----------- --------------------
  **Model 1**                                                                                               
  Leukopenia               *FKBP2* c.-2110G\>T        GG genotype          4.45 (1.81--20.11)   0.017       0.085
                           CMV                        Use of ganciclovir   6.85 (1.81--26.02)   0.005       0.030
  **Model 2**                                                                                               
  Constipation             *FKBP1A* n.259+24936T\>C   TC+CC genotype       2.41 (1.05--7.92)    0.030       0.150
  Epigastric pain          *FOXP3* c.-22-902A\>G      GA+AA genotype       2.41 (1.05--6.33)    0.022       0.115
  Nausea and/or vomiting   *FOXP3* c.-23+2882A\>C     CA+AA genotype       2.24 (0.89--6.23)    0.063       0.189

Model 1: Adjusted for recipient weight, age and gender, therapy group and treatment for cytomegalovirus. Model 2: Adjusted for recipient weight, age and gender and therapy group. Adjusted p-value was estimated using the Bonferroni--Holm sequential correction method. OR, odds ratio; CI, confidence interval.

Discussion
==========

This study investigated the influence of polymorphisms in genes of the mTOR and calcineurin signaling pathway on long-term clinical outcomes in kidney recipients treated with TAC and EVR-based immunosuppressive therapy. Factors related to long-term acute rejection and adverse events were also investigated. Pre-transplant clinical and laboratory characteristics of the kidney recipients were similar among the immunosuppressive therapy groups, as it was previously reported ([@B33]). Interestingly the TAC10/EVR group had lower eGFR and higher serum creatinine than TAC10/MPS at 1-year post-transplant.

A meta-analysis examined long-term renal outcomes comparing different immunosuppressant regimens. The authors observed that cohorts using combination of non-reduced doses of CNI and mycophenolic acid, as compared with mTORi group, showed higher creatinine clearance and lower serum creatinine values ([@B39]). Therefore, in agreement to our results, the combination of traditional CNI regimens and MPS might lead to better renal function. In a large Brazilian single-center study, after 1 year, no differences in eGFR values were found between *de novo* use of mTORi or antimetabolites, such as mycophenolic acid, in combination with CNIs ([@B5]), but a higher proportion of living donors could have influenced this result.

In this study, *MTOR* c.1437T\>C (CC genotype) was associated with higher serum creatinine, but this variant did not influence eGFR at 1-year post-transplant. No previous study evaluated the relationship between *MTOR* variants and renal outcomes in kidney recipients. *MTOR* c.1437T\>C (p.Asp479=) does not cause a functional disruption in the mTOR protein, which could be related to a worst renal outcome. It is conceivable that this variant is in linkage disequilibrium with a pathogenic variant within *MTOR*.

*MTOR* c.1437T\>C was reported to be linked to the *MTOR* rs2295080 (c.-141C\>A), a promoter variant, of which GT genotype was previously associated with less risk for prostate cancer ([@B17]). Further *in vitro* experiments with luciferase reporter in normal or cancer gastric cell lines (GES-1, BGC823, MGC803, and SGC-7901) revealed a higher transcription activity in the presence of the T allele of rs2295080 ([@B40]).

It is likely that the C allele of *MTOR* c.1437T\>C is correlated with the T allele of *MTOR* rs2295080 (c.-141C\>A), and the higher mTOR transcriptional levels might lead to a worst renal outcome due to insufficient immunosuppressive activity of EVR.

Carriers of the G allele of *MTOR* c.4731G\>A (genotype AG+GG) were found to present higher incidence of acute rejection episodes during the first-year post-transplant. Regression analysis showed that G allele of the *MTOR* c.4731G\>A polymorphism was associated with increased risk for long-term acute rejection in kidney transplants. This variant, which is in linkage disequilibrium with *MTOR* c.1787-116A\>G, was previously reported to be associated with high risk for colon cancer in a sample from United States ([@B31]). Also, the *MTOR* c.1787-116AA genotype was associated with reduced *MTOR* mRNA expression in healthy colon tissue ([@B32]).

These evidences are suggestive that the subjects carrying the *MTOR* c.4731G allele may have lower *MTOR* transcript levels, which could be associated with increased incidence of acute rejection. Besides, the *MTOR* variants, mainly *MTOR* c.1787-116A\>G (rs2024627), were recommended as genetic markers of pharmacogenetics of kidney transplant ([@B27]). Finally, patient variability within the efficacy kidney outcomes may rely on the *MTOR* variants yet to be studied.

Alloantigens are immunomodulatory molecules that stimulate T cell receptor ([@B11]); upon its activation, mTOR is activated, which in turn regulates T cell fate ([@B4]). Immunosuppressant agents targeting mTOR as EVR inhibit the transduction of interleukin-2 stimulus in T cells causing a cell-cycle arrest ([@B18]). On those alloactivated T cells, mTOR inhibitors might reduce the immune response toward the graft, avoiding acute rejection episodes through the reduction of mTOR levels.

mTOR signaling pathway also exerts a role regulating the differentiation of regulatory and effectors T cells ([@B43]), and its activation led to the proliferation and suppressive activity of Tregs. In this way, inactivation of the mTOR pathway could also led to a lower activity of Tregs, and subsequent autoimmunity problems ([@B44]). In agreement to our hypothesis, the lower expression of mTOR could turn the graft more vulnerable to immune responses, and subsequent acute rejection episodes. Therefore, in spite of mechanistic explanations for acute rejection and *MTOR* variants, the relevance of polymorphisms in the mTOR signaling pathway is pointed out by our study.

*MTOR* variants were not associated with long-term adverse events in this work, in spite of a previous study reported a relationship of other *MTOR* polymorphisms with low hemoglobin levels in kidney recipients treated with sirolimus-based immunosuppressive therapy ([@B36]).

In this study, the CC genotype of the *FOXP3* c.-23+2882A\>C was associated with higher serum creatinine pre- and post-transplant in kidney recipients. It is likely that *FOXP3* c.-23+2882CC genotype may account for a worse renal function. On the other hand, a previous study showed that individuals carrying the CC genotype had increased eGFR values and TAC blood levels in kidney recipients at 21 days post-transplant ([@B8]). These results are suggestive that the influence of this *FOXP3* variant on renal function may depend on the time of exposure to TAC.

Additional analysis used an additive model, which grouped male hemizygous genotypes with each one of the corresponding female homozygous genotypes. Our results indicated that females carrying the CA genotype, but not CC/C, of the *FOXP3* c.-23+2882A\>C had a higher risk of serum creatinine compared to the individuals carrying the AA/A genotypes/alleles (data not shown). Subgroup analysis in small samples could lower statistical power. Besides, disparity in the frequency distribution of the female heterozygotes could also have influenced this result.

One study explored the impact of *FOXP3* polymorphisms on the long-term renal outcomes in patients receiving a cyclosporine-based treatment. *FOXP3* c.-22-2361C\>T but not c.-23+2882A\>C was associated with lower eGFR values. To our knowledge, this is the only study which explored *FOXP3* polymorphisms considering hemizygous males ([@B41]), and even though did not report any association for *FOXP3* c.-23+2882A\>C polymorphism, it drew the attention to these group of genetic variants.

*FOXP3* c.-22-902A\>G and c.-23+2882A\>C polymorphisms were not related to long term acute rejection in kidney recipients, even when the analysis was carried out considering male as hemizygous and grouping with correspondent homozygous genotypes (data not shown). A previous study also did not find association of both *FOXP3* variant with acute or chronic rejection, even in a 10-years follow-up period ([@B24]). On the other hand, other studies reported association of the *FOXP3* c.-23+2882A\>C (A allele) polymorphism with long-term (2 and 5 years) acute rejection or nephrotoxicity in kidney recipients from different populations treated with cyclosporine- or TAC- based immunosuppressive therapy ([@B28]; [@B21]; [@B38]). The c.-23+2882A allele was also associated with worst graft survival and higher rate of recurrence of the original glomerular disease in kidney recipients at 3-year post-transplant ([@B1]).

*FOXP3* variants are associated with susceptibility to autoimmune diseases and infections ([@B7]; [@B14]), but the underlying mechanisms are poorly understood. The *FOXP3* c.-23+2882A\>C variant can cause loss of binding of transcriptional factors to the "GGGCGG" sequence located in the core of the promoter region, altering the transcription of the gene ([@B23]). Functional analysis demonstrated the A allele of *FOXP3* c.-23+2882A\>C decreased the promoter activity ([@B30]), however, this finding is not reliable since the article was retracted. Therefore, more studies are needed in order to clarify whether the *FOXP3* polymorphism behaves as a risk or protective factor for renal function.

Interestingly both *FOXP3* c.-22-902A\>G and c.-23+2882A\>C were associated with long-term gastrointestinal adverse effects, but this association was not maintained in the multivariable analysis after *p*-value adjustment, even when the patients were analyzed with the additive model (data not shown). To our knowledge, there is no report investigating the effect of *FOXP3* variants in the occurrence of adverse events.

Likewise, an association between the C allele of *FKBP1A* n.259+24936T\>C and constipation was also found but this relationship was not sustained after Holm's p-value adjustment. Moreover, *FKBP2* c.-2110G\>T was associated with adverse event (leukopenia) but not with renal dysfunction or acute rejection in this sample population. However, this relationship did not remain after p-value adjustment in the multivariable logistic regression model.

Both MPS-based immunosuppressive therapy and ganciclovir were also individually associated with leukopenia, but only the latter remained significant after adjustment. It is likely that carriers of the GG genotype of *FKBP2* c.-2111G\>T are more responsive to immunosuppressive drugs. Additional analysis showed that the GG genotype and the use of ganciclovir were not associated (data not shown). This might imply that CMV treatment is a strong predictor for leukopenia events rather than the *FKBP2* c.-2110G\>T variant.

It has been described that up to 35% of patients under treatment with MPS develops episodes of leukopenia ([@B42]). Another factor causing this drug adverse effect is the use of ganciclovir ([@B19]). Thus, individuals with susceptible genotypes could be exposed to a higher risk of leucopenia, which is favorable to the effect of immunosuppressive agents.

In our work, among the non-genetic factors influencing kidney outcomes, the time of DGF was strongly associated with acute rejection, even in the presence of other confounders such as recipient and donor factors or cold ischemia time. Likewise, in a cohort of kidney recipients treated with TAC-based therapy, the presence of DGF was associated with increased risk of acute rejection ([@B37]). These findings emphasize careful surveillance of patients with DGF in order to mitigate possible episodes of acute rejection.

To best of our knowledge, this is the first study to investigate the association of *MTOR*, *FKBP1A*, *FKBP2* and *FOXP3* polymorphisms with renal function, acute rejection and drug-related adverse events in Brazilian kidney recipients.

The small sample size and the population substructure are limitations of this study, and in particular, the low number of female patients for the analysis of polymorphisms located in the X chromosome. The low number of cases with acute rejection and graft failure also limited the study of associations between these outcomes and polymorphisms. Also a heterogeneity in the therapeutic regimens of calcineurin and mTOR inhibitors for every study group is observed. The analyses of this work are exploratory considering that the main study was not designed to evaluate pharmacogenetic aspects.

Conclusion
==========

In conclusion, this work shows that *MTOR* variants are associated with long-term kidney outcomes, in particular, with acute rejection and renal function. Furthermore, the variants in *FKBP2*, *FKBP1A*, and *FOXP3* were individually associated with the occurrence of drug-related adverse events.
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Co/D

:   drug concentration for dose administered

CKD

:   chronic kidney disease

CMV

:   cytomegalovirus

CNI

:   calcineurin inhibitor

DGF

:   delayed graft function

eGFR

:   estimated glomerular filtration rate

EVR

:   everolimus

MPS

:   mycophenolate sodium

mTOR

:   mechanistic target of rapamycin

mTORi

:   mTOR inhibitor

TAC

:   tacrolimus

Tregs

:   regulatory T cells.
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